Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  BioPorto A/S    BIOPOR   DK0011048619

BIOPORTO A/S (BIOPOR)

Delayed Quote. Delayed  - 09/23 04:52:37 pm
1.89 DKK   --.--%
08/08 BIOPORTO A/S : Jan Kuhlmann Andersen new COO in BioPorto A/S - resig..
08/04 BIOPORTO A/S : Interim report, first half of 2016
07/06 BIOPORTO A/S : BioPortos NGAL Exclusion patent is ruled invalid by t..
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
09/19/2016 09/20/2016 09/21/2016 09/22/2016 09/23/2016 Date
2.1(c) 2.08(c) 2.01(c) 1.89(c) 1.89(c) Last
136 926 198 201 527 353 1 446 494 363 389 Volume
-0.94% -0.95% -3.37% -5.97% 0.00% Change
More quotes
Company
BioPorto A/S is an in-vitro diagnostics company.It provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies.The company focuses on the diagnosis of obesity, diabetes, primary immune deficiency, and kidney injury.Its products include The NGAL... 
Sector
Pharmaceuticals
Calendar
11/03Earnings Release
More about the company
Latest news on BIOPORTO A/S
08/08 BIOPORTO A/S : Jan Kuhlmann Andersen new COO in BioPorto A/S - resigns from the ..
08/04 BIOPORTO A/S : Interim report, first half of 2016
07/06 BIOPORTO A/S : BioPortos NGAL Exclusion patent is ruled invalid by the EPO BioPo..
07/05 BIOPORTO A/S : NGAL Exclusion patent is ruled invalid by the EPO – to appe..
07/04 BIOPORTO A/S : decides to reapply for FDA approval of The NGAL TestTM
06/07 BIOPORTO A/S : Clinical Leaders Reinforce Belief in NGAL for Detection of AKI Fo..
06/06 Clinical Leaders Reinforce Belief in NGAL for Detection of AKI Following FDA'..
06/06 BIOPORTO A/S : Clinical Leaders Reinforce Belief in NGAL for Detection of AKI Fo..
05/28 BIOPORTO A/S : The FDA rejects application for the registration og The NGAL Test..
05/19 BIOPORTO A/S : BioPortos NGAL Forms patent is upheld after EPO ruling
More news
Sector news : Diagnostic & Testing Substances Manufacturers
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Other Events
More sector news : Diagnostic & Testing Substances Manufacturers
Advertisement
Chart BIOPORTO A/S
Duration : Period :
BioPorto A/S Technical Analysis Chart | BIOPOR | DK0011048619 | 4-Traders
Full-screen chart
Technical analysis trends BIOPORTO A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Managers
NameTitle
Peter Mørch Eriksen CEO & Investor Relations Contact
Thomas Magnussen Chairman
Jan Kuhlmann Andersen Chief Operating Officer
Jakob Brix Christensen Chief Financial Officer
Torben A. Nielsen Vice Chairman
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOPORTO A/S-60.79%0
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results